C-CAR031 is based on a novel GPC3-targeting CAR-T (AZD5851) designed by AstraZeneca using their transforming growth factor-beta receptor II
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
This fresh infusion of capital will enable ImmunoACT to fast track the additional supply of the lead candidate HCAR-19
Company creates Younger T Cells for fighting cancer using its NR2F6 technology
Shoreline has developed a proprietary methodology to create differentiated iNK cells for large-scale, "off-the-shelf" production
This is the first CAR T cell therapy application filed for the second-line treatment of R/R LBCL in Japan
The sNDA was supported by the clinical results from cohort B of a single-arm, multi-center, pivotal study (RELIANCE study) on Carteyva in adult patients with relapsed or refractory B cell non-hodgkin lymphoma in China
Application based on the pivotal Phase 3 TRANSFORM study in which Breyanzi showed significant and clinically meaningful improvements over salvage chemotherapy followed by high-dose chemotherapy plus autologous stem cell transplant, which has been the standard of care for more than 20 years
It is the first CAR T Therapy approved for the treatment of multiple myeloma in Japan
Subscribe To Our Newsletter & Stay Updated
